Publication: Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers
Issued Date
1996-01-01
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-0029916970
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.14, No.4 (1996), 329-336
Suggested Citation
David W. Vaughn, Charles H. Hoke, Sutee Yoksan, Rebecca LaChance, Bruce L. Innis, Robert M. Rice, Natth Bhamarapravati Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. Vol.14, No.4 (1996), 329-336. doi:10.1016/0264-410X(95)00167-Y Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/17572
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers
Abstract
A live-attenuated dengue 2 vaccine (strain 16681 PDK 53) developed at Mahidol University, Thailand was evaluated for safety and immunogenicity by administering 104p.f.u. subcutaneously to ten flavivirus non-immune American volunteers. The vaccine was safe; there were no serious adverse reactions. Eight recipients experienced no or mild side effects. One recipient reported headaches on 7 separate days. One volunteer, who had a fracture of the humerus 1 day after vaccination requiring surgical repair, experienced generalized malaise with fever (maximum temperature = 38.9°C), headache, eye pain and myalgia lasting less than 24 h. The vaccine was highly immunogenic; all recipients developed neutralizing antibody that persisted for two years.